8-K: Acrivon Therapeutics Secures $130 Million in Private Placement to Advance Pipeline

Acrivon Therapeutics has successfully raised $130 million through a private placement to fund the development of its precision oncology pipeline.

Summary

• Acrivon Therapeutics has entered into a securities purchase agreement for a private placement, raising approximately $130 million.
• The private placement involves the issuance of 8,235,000 shares of common stock at $8.50 per share and pre-funded warrants to purchase up to 7,060,000 shares at $8.499 per warrant.
• The pre-funded warrants are exercisable at $0.001 per share and do not expire.
• The financing is expected to close on April 11, 2024, subject to customary closing conditions.
• The company intends to use the net proceeds to advance its pipeline, including ACR-368 and ACR-2316, and its cell cycle regulatory program.
• Funds will also support research and development of the AP3 platform, leveraging AI and machine learning, and for general corporate purposes.
• Jefferies LLC acted as the sole placement agent for the private placement.

Sentiment

Score: 8

Explanation: The document conveys a highly positive sentiment due to the successful oversubscribed capital raise, the premium share price, and the strong investor backing. The company's clear plan for the use of funds and the extended cash runway further contribute to the positive outlook.

Positives

• The private placement was oversubscribed, indicating strong investor interest.
• The financing includes both new and key existing investors.
• The company has secured sufficient funding to support operations into the second half of 2026.
• The company has flexibility to extend funding further.
• The company is advancing its lead clinical asset, ACR-368, in registrational-intent Phase 2 trials.

Negatives

• The company has agreed not to issue any shares of Common Stock or Common Stock equivalents for a lock-up period of 60 days after the closing of the Private Placement or until the Registration Statement is declared effective by the SEC.

Risks

• The closing of the private placement is subject to customary closing conditions.
• The company's future performance depends on the successful advancement of its pipeline and platform.
• The company is subject to risks and uncertainties described in its SEC filings.

Future Outlook

Acrivon expects the net proceeds from the private placement, along with existing cash, to fund operations into the second half of 2026, with flexibility to extend further.

Management Comments

• We are excited to announce this financing and thank our new and key existing investors who have shown their support for and confidence in Acrivon, said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
• With this funding, we are well positioned to continue the advancement of our lead clinical asset, ACR-368, currently in registrational-intent Phase 2 trials, as well as our preclinical pipeline including ACR-2316, our internally-discovered, novel WEE1/PKMYT1 inhibitor and our recently declared cell cycle regulatory program with an undisclosed target.
• I am particularly excited about the enthusiasm for the broad potential of Acrivons differentiated AP3 platform and their support for our compelling long-term strategy aiming to transform precision medicine for the benefit of patients.

Industry Context

This private placement reflects continued investor interest in the precision oncology space and companies with innovative platforms like Acrivon's AP3. The funding will allow Acrivon to further develop its pipeline and potentially compete with other companies in the targeted cancer therapy market.

Comparison to Industry Standards

• The private placement is a common method for biotech companies to raise capital, especially those in the clinical stage.
• The valuation of the shares at $8.50 per share, a premium to the closing price on April 8, 2024, suggests a positive market perception of Acrivon's potential.
• The inclusion of pre-funded warrants is a typical structure in private placements, allowing investors to participate in future upside.
• The involvement of well-known healthcare investors like RA Capital Management and Perceptive Advisors indicates confidence in Acrivon's technology and management.
• The stated runway into the second half of 2026 is a positive sign for investors, providing a clear timeline for the company's development plans.

Stakeholder Impact

• Shareholders will benefit from the company's strengthened financial position and ability to advance its pipeline.
• Employees will have increased job security and opportunities for growth.
• Customers (patients) may benefit from the development of new precision oncology medicines.
• Suppliers and creditors will have increased confidence in the company's financial stability.

Next Steps

• The company will close the private placement on April 11, 2024.
• The company will file a registration statement with the SEC to register the resale of the securities sold in the private placement.
• The company will continue to advance its pipeline, including ACR-368 and ACR-2316.
• The company will continue to develop its AP3 platform and leverage AI/machine learning.

Key Dates

Keywords

private placement, capital raise, precision oncology, biopharmaceutical, ACR-368, ACR-2316, AP3 platform, proteomics, clinical trials, Jefferies